glp 1 coverage for weight loss Perspectives from employers on the costs and issues associated with covering GLP-1 agonists Metabolic surgery and GLP-1 agonists

AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease

BNPL acceptance for tirzepatide breaks down into three categories: online telehealth platforms, in-person medical spas and clinics, and compounding pharmacies

[DOI] [PubMed] [Google Scholar] 56.Chertow GM, Vart P, Jongs N, Toto RD, Gorriz JL, Hou FF, et al

Originally developed as a treatment for diabetes, uptake has been staggering since the drugs were approved for weight loss, reflecting GLP-1s efficacy and growing acceptance

Tirzepatide has a dual-action mechanism, targeting multiple hormone pathways

Patients experiencing shortness of breath while taking tirzepatide should seek immediate medical attention if they develop any of the following warning signs: Seek emergency care immediately (call 911) for: Sudden onset of severe shortness of breath or difficulty breathing Chest pain, pressure, or tightness accompanying breathing difficulties Rapid heart rate, palpitations, or irregular heartbeat Swelling of the face, lips, tongue, or throat (suggesting anaphylaxis) Wheezing, stridor, or audible breathing difficulty Confusion, lightheadedness, or loss of consciousness Blue discoloration of lips or fingertips (cyanosis) These symptoms may indicate serious conditions requiring urgent evaluation, including acute coronary syndrome, pulmonary embolism, severe allergic reaction, or acute heart failure